Not All Japanese Companies Bothered By New Pharma Sales Law
This article was originally published in PharmAsia News
Executive Summary
Japan's June 1 effective date for its Pharmaceutical Affairs Law has presented a mixed bag for the drug industry, patients and a variety of new entrants into the business of selling medicines. Although the new law expanding some over-the-counter sales to convenience stores and shutting down a lot of online sales has claimed winners and losers, Daigen Pharmaceutical is experiencing a 50 percent increase in orders for its online products, such as an athlete's foot treatment. Daigen is benefiting, however, from a two-year window allowing continued online sales of drugs to people who already had been buying them before June 1. (Click here for more - a subscription may be required
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.